Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NONPROFIT ORGANIZATIONS' UNRELATED BUSINESS INCOME TAX

Executive Summary

NONPROFIT ORGANIZATIONS' UNRELATED BUSINESS INCOME TAX was discussed at a closed-door meeting of the House Ways and Means/Oversight Subcommittee August 2. Subcommittee Chairman Pickle (D-Tex.) called the meeting in an effort to move the subcommittee's 1988 recommendations on UBIT issues to the full committee for review. Ways and Means Chairman Rostenkowski (D-Ill.) has indicated that he wants the full committee to assess the recommendations, according to subcommittee staff. The subcommittee reportedly made no progress in terms of selecting specific legislative recommendations. Pickle asked members to familiarize themselves with UBIT issues during the summer recess. He is planning to hold another subcommittee session on UBIT in September. Last year, the panel developed a list of possible changes in the UBIT law to tax certain activities of nonprofit entities. One option floated by the subcommittee would require nonprofits to pay tax on sales and rentals of pharmaceuticals and medical equipment.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

Latest Headlines
See All
UsernamePublicRestriction

Register

PS016051

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel